CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan
The two industry leaders focus on navigating the biotech industry and immuno-oncology research
LEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) — CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Pyxis Oncology President & CEO, Dr. Lara Sullivan, discussed her journey as a biotech entrepreneur and executive at Pfizer.
“My role at Pfizer was an incredible biotech training course and I didn’t even know it at the time because I was in the heart of Pfizer’s innovation engine when Pfizer was the world’s biggest pharma company,” said Dr. Sullivan. “They were reinventing their R&D approach with more efficient processes, while also placing a greater emphasis on innovation. Drug development is an apprenticeship model just like medicine.”
“We gained a number of insights from this discussion that can be applied to our own research,” said CancerVax CEO, Ryan Davies. “As we continue the fight against Cancer, we can benefit greatly by learning from the experiences of others within our industry.”
Dr. Lara S. Sullivan is the President and Chief Executive Officer of Pyxis Oncology. Prior to joining Pyxis Oncology, Dr. Sullivan was Founding President of SpringWorks Therapeutics, a clinical stage biopharmaceutical company she conceived of, founded, and spun out from Pfizer. As a biotech entrepreneur and advisor, Dr. Sullivan has leveraged her expertise in asset evaluation, portfolio management, and start-up financing to raise nearly $500 million of capital from seed stage through IPO. While at Pfizer, Dr. Sullivan held a variety of executive roles including Vice President, Pfizer Medical and Vice President, Worldwide Research & Development, where she led strategy, competitive intelligence and portfolio operations for the company’s early-stage R&D pipeline. Earlier in her career, she held a variety of roles in management consulting, private equity, and investment banking. Dr. Sullivan holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.
This Podcast can be viewed at https://www.youtube.com/watch?v=nb4DZ-G49c8
For more information about CancerVAX, please visit http://www.cancervax.com/.
About Us
CancerVAX, Inc. is a pre-clinical biotechnology company developing a breakthrough universal cancer vaccine to fight cancer using the body’s immune system. Working with a team of experienced cancer researchers and physicians at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with incredible precision. Like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s immune system to destroy cancer cells. As we develop our universal cancer vaccine, we work with UCLA to develop single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. We look forward to the day when treating cancer will be as simple as getting a flu shot.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Press Contact:
CancerVAX, Inc.
Tel: (805) 356-1810
communications@CancerVAX.com
